Guilin Sanjin Pharmaceutical (002275.SZ) announced its third quarter report for 2024 on October 29. In the first three quarters of 2024, the company achieved revenue of 1.575 billion yuan, a decrease of 3.49% year-on-year; net income attributable to the shareholders of the listed company was 0.384 billion yuan, a decrease of 3.28% year-on-year; net income after deducting non-recurring gains and losses was 0.347 billion yuan, a decrease of 7.78% year-on-year; basic earnings per share were 0.65 yuan per share.
桂林三金(002275.SZ)：前三季度净利润3.84亿元，同比下降3.28%
Guilin Sanjin Pharmaceutical (002275.SZ): The net income for the first three quarters was 0.384 billion yuan, a 3.28% year-on-year decrease.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated